RBC Lifts Price Target on Agios Pharmaceuticals to $42 From $40 as Phase 2 Trial of Sickle Cell Disease Treatment Meets Primary Endpoint; Outperform Kept
RBC Lifts Price Target on Agios Pharmaceuticals to $42 From $40 as Phase 2 Trial of Sickle Cell Disease Treatment Meets Primary Endpoint; Outperform Kept
加拿大皇家银行将Agios Pharmicals的目标股价从40美元上调至42美元,原因是镰状细胞病治疗的第二阶段试验达到主要终点;表现保持跑赢大盘
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册